Table 3. Alcohol consumptions and differentiated thyroid cancer by clinicopathologic features, T-CALOS April 2010–April 2014.
| Case1 | OR (95% CI)2 | Case1 | OR (95% CI) 2 | Case1 | OR (95% CI) 2 | Case1 | OR (95% CI) 2 | |
|---|---|---|---|---|---|---|---|---|
| Tumor size≤1cm | Tumor size>1cm | LN metastasis (-) | LN metastasis (+) | |||||
| Alcohol intake (g) per event | ||||||||
| Never | 833 | 1.00 (Reference) | 334 | 1.00 (Reference) | 716 | 1.00 (Reference) | 385 | 1.00 (Reference) |
| 0–50 | 369 | 0.80 (0.69–0.92) | 140 | 0.81 (0.65–1.00) | 313 | 0.85 (0.73–0.98) | 156 | 0.68 (0.56–0.83) |
| 51–150 | 222 | 1.09 (0.89–1.32) | 97 | 1.18 (0.89–1.57) | 155 | 1.08 (0.87–1.35) | 142 | 1.14 (0.89–1.46) |
| 151+ | 14 | 1.11 (0.59–2.11) | 11 | 2.23 (1.09–4.53) | 11 | 1.22 (0.60–2.47) | 15 | 1.87 (0.99–3.50) |
| p-trend4 | 0.469 | 0.570 | 0.822 | 0.746 | ||||
| Duration (years) | ||||||||
| Never | 833 | 1.00 (Reference) | 334 | 1.00 (Reference) | 716 | 1.00 (Reference) | 385 | 1.00 (Reference) |
| 0–20 | 337 | 0.76 (0.65–0.88) | 135 | 0.84 (0.67–1.05) | 270 | 0.79 (0.67–0.93) | 172 | 0.72 (0.58–0.88) |
| 21–30 | 210 | 0.93 (0.78–1.12) | 81 | 0.90 (0.68–1.18) | 170 | 1.00 (0.82–1.22) | 107 | 0.83 (0.65–1.06) |
| 31+ | 132 | 1.80 (1.41–2.29) | 76 | 2.14 (1.56–2.95) | 107 | 1.95 (1.50–2.54) | 79 | 1.89 (1.39–2.57) |
| p-trend4 | 0.077 | 0.012 | 0.011 | 0.258 | ||||
| ETE (-) | ETE (+) | TNM stage I | TNM stage II-IV | |||||
| Alcohol intake (g) per event | ||||||||
| Never | 468 | 1.00 (Reference) | 682 | 1.00 (Reference) | 817 | 1.00 (Reference) | 300 | 1.00 (Reference) |
| 0–50 | 254 | 0.98 (0.83–1.16) | 249 | 0.69 (0.59–0.81) | 393 | 0.80 (0.70–0.92) | 99 | 0.75 (0.58–0.95) |
| 51–150 | 148 | 1.28 (1.01–1.63) | 164 | 0.97 (0.78–1.21) | 236 | 1.08 (0.89–1.32) | 72 | 1.17 (0.84–1.62) |
| 151+ | 11 | 1.51 (0.75–3.08) | 14 | 1.39 (0.74–2.62) | 19 | 1.39 (0.77–2.51) | 7 | 1.87 (0.81–4.33) |
| p-trend4 | 0.119 | 0.051 | 0.538 | 0.767 | ||||
| Duration (years) | ||||||||
| Never | 468 | 1.00 (Reference) | 682 | 1.00 (Reference) | 817 | 1.00 (Reference) | 300 | 1.00 (Reference) |
| 0–20 | 232 | 0.92 (0.77–1.10) | 227 | 0.67 (0.56–0.79) | 415 | 0.81 (0.70–0.94) | 54 | 0.53 (0.39–0.73) |
| 21–30 | 145 | 1.15 (0.92–1.43) | 145 | 0.79 (0.64–0.97) | 217 | 0.93 (0.78–1.12) | 72 | 1.08 (0.80–1.44) |
| 31+ | 86 | 2.15 (1.61–2.87) | 117 | 1.73 (1.34–2.23) | 103 | 1.81 (1.40–2.36) | 83 | 1.90 (1.38–2.62) |
| p-trend4 | <0.001 | 0.564 | 0.138 | 0.013 | ||||
| Age at diagnosis <45 | Age at diagnosis ≥45 | BRAFwt in PTC3 | BRAFV600E in PTC3 | |||||
| Alcohol intake (g) per event | ||||||||
| Never | 293 | 1.00 (Reference) | 896 | 1.00 (Reference) | 349 | 1.00 (Reference) | 763 | 1.00 (Reference) |
| 0–50 | 213 | 0.79 (0.62–0.99) | 306 | 0.69 (0.60–0.79) | 156 | 0.91 (0.74–1.12) | 326 | 0.83 (0.72–0.96) |
| 51–150 | 151 | 1.23 (0.91–1.67) | 176 | 1.21 (0.97–1.50) | 73 | 1.12 (0.82–1.54) | 229 | 1.49 (1.23–1.81) |
| 151+ | 10 | 1.79 (0.72–4.48) | 17 | 1.88 (1.02–3.47) | 6 | 2.59 (1.03–6.54) | 20 | 2.89 (1.72–4.86) |
| p-trend4 | 0.735 | 0.389 | 0.280 | 0.017 | ||||
| Duration (years) | ||||||||
| Never | 293 | 1.00 (Reference) | 896 | 1.00 (Reference) | 349 | 1.00 (Reference) | 763 | 1.00 (Reference) |
| 0–20 | 319 | 0.73 (0.58–0.91) | 164 | 0.58 (0.48–0.70) | 123 | 0.69 (0.54–0.87) | 324 | 0.82 (0.70–0.95) |
| 21–30 | 101 | 2.83 (2.05–3.90) | 200 | 1.23 (1.02–1.48) | 89 | 1.41 (1.07–1.85) | 192 | 1.18 (0.98–1.43) |
| 31+ | 1 | 0.19 (0.01–61.69) | 211 | 2.08 (1.68–2.59) | 51 | 2.87 (1.91–4.34) | 136 | 2.03 (1.58–2.61) |
| p-trend4 | <0.001 | <0.001 | <0.001 | <0.001 |
Abbreviations: OR = odds ratio; 95% CI = 95% confidence interval; LN metastasis = lymph node metastasis; BRAFwt in PTC = negative for BRAF (V600E) by mutation testing; BRAFV600E in PTC = positive for BRAF (V600E) by mutation testing; PTC = papillary thyroid cancer; DTC = differentiated thyroid cancer; ETE (-) = absence of extrathyroidal extension; ETE (+) = presence of extrathyroidal extension.
1. Subjects with missing information for alcohol intake per event with FTC (5 men and 4 women) and PTC (50 men and 136 women) were identified. DTC patients with information on tumor size (<1 cm = 1,567 cases; ≥1 cm = 644 cases), LN metastasis (No = 1,311 cases; Yes = 764 cases) and TNM staging (stage I = 1,606 cases; stage II = 41 cases; stage III = 406 cases; and stage IV = 79 cases), and ETE (No = 977 cases; Yes = 1,198 cases) and the controls were included.
2. Polychotomous logistic regression models (controls vs. less advanced cases; and controls vs. more advanced cases) were adjusted for matching variables (age, sex and enrollment year), education level, marital status, smoking, regular exercise, and history of chronic diseases, including hypertension and dyslipidemia.
3. ORs and 95%CIs were calculated for the PTC patients with information on BRAF mutation status (2,092 cases) and their matched controls using conditional logistic regression models adjusted for education level, marital status, smoking, regular exercise, and history of chronic diseases, including hypertension and dyslipidemia (diagnosed by a medical doctor: never, ever and unknown).
4. A p-trend was calculated for dose response associations.